Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

HeartcoR Solutions, a leading ECG core lab that conducts cardiac safety studies for the pharmaceutical, medical device, and ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...

The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.